BridgeBio Pharma (BBIO) Peer Comparison

$77.89

$3.86 (5.21%)

As on 04-Nov-2026 16:00EST

Market cap

$14,600 Mln

Revenue (TTM)

$946 Mln

P/E Ratio

--

P/B Ratio

123.7

Div. Yield

0 %

Edit

	BridgeBio Pharma (BBIO)	Dr. Reddy's Laboratories - ADR	Ligand Pharmaceuticals (LGND)	Supernus Pharmaceuticals (SUPN)	Eli Lilly and Company (LLY)
Market cap ($ Mln)	14,600	11,755	6,434	2,441	1,262,667
Revenue ($ Mln)	946	331,377	254	865	86,462
Net Profit ($ Mln)	-570.21	28,032.40	51.46	-43.86	27,579.70
Net Margin (%)	-60.30	8.46	20.27	-5.07	31.90
RoE (%)	--	7.51	5.25	-4.10	77.18
Price to Earnings	--	39.19	34.01	--	46.11
Price-To-Book	123.68	2.91	6.65	2.30	31.35

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	BridgeBio Pharma (BBIO)	Dr. Reddy's Laboratories - ADR	Ligand Pharmaceuticals (LGND)	Supernus Pharmaceuticals (SUPN)	Eli Lilly and Company (LLY)
Operating Revenue	945.54	331,377.21	253.83	865.11	86,462.00
Cost of Revenue	61.34	167,448.74	-18.05	107.09	14,149.70
Gross Profit	473.81	190,428.00	261.50	644.39	54,127.00
Operating Expenses	1,294.12	134,367.32	241.64	789.32	32,481.90
Operating Profit (EBIT)	-409.91	29,561.14	30.24	-30.40	39,830.40
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-578.95	35,270.62	52.73	-42.80	34,769.20
Provision for Tax	-4.96	7,639.53	1.27	1.05	7,189.50
Profit after Tax (Net Income)	-570.21	28,032.40	51.46	-43.86	27,579.70
Minority Interest	11.75	401.00	0.00	0.00	0.00
Consolidated Profit	0.00	12,099.00	0.00	0.00	6,636.00

Liabilities ($ Mln)

	BridgeBio Pharma (BBIO)	Dr. Reddy's Laboratories - ADR	Ligand Pharmaceuticals (LGND)	Supernus Pharmaceuticals (SUPN)	Eli Lilly and Company (LLY)
Shareholder's Funds	-1,662.34	387,871.57	961.76	1,062.48	40,271.00
Minority Interest	11.75	401.00	0.00	0.00	0.00
Non-Current Liabilities	2,838.05	30,754.20	1,172.05	49.82	60,805.00
Current Liabilities	977.24	155,168.12	39.76	285.40	46,996.00
Total Liabilities	936.03	492,989.00	1,560.64	1,452.65	112,476.00

Assets ($ Mln)

	BridgeBio Pharma (BBIO)	Dr. Reddy's Laboratories - ADR	Ligand Pharmaceuticals (LGND)	Supernus Pharmaceuticals (SUPN)	Eli Lilly and Company (LLY)
Non-Current Assets	117.18	278,119.64	800.11	686.48	82,809.00
Current Assets	2,044.61	298,879.23	530.62	711.22	65,263.00
Total Assets	936.03	492,989.00	1,560.64	1,452.65	112,476.00
Total Debt*	2,494.05	72,603.83	1,128.22	36.20	49,503.00
Net Current Assets	1,067.37	143,084.00	0.00	0.00	18,267.00

Cashflow ($ Mln)

	BridgeBio Pharma (BBIO)	Dr. Reddy's Laboratories - ADR	Ligand Pharmaceuticals (LGND)	Supernus Pharmaceuticals (SUPN)	Eli Lilly and Company (LLY)
Cash From Operating Activities	-445.91	46,428.00	49.36	47.33	16,813.00
Cash Flow from Investing Activities	-24.49	-58,077.00	-377.32	4.11	-10,972.00
Cash from Financing Activities	359.29	18,911.00	428.22	9.13	-2,213.00
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	BridgeBio Pharma (BBIO)	Dr. Reddy's Laboratories - ADR	Ligand Pharmaceuticals (LGND)	Supernus Pharmaceuticals (SUPN)	Eli Lilly and Company (LLY)
ROCE (%)	-159.44	16.61	10.79	-3.55	35.32
ROE (%)	41.15	7.51	5.25	-4.10	77.18
ROA (%)	-26.19	3.93	2.41	-2.27	15.75
EBIT Margin (%)	-47.10	9.79	38.83	-4.18	49.24
Net Margin (%)	-60.30	8.46	20.27	-5.07	31.90
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	BridgeBio Pharma (BBIO)	Dr. Reddy's Laboratories - ADR	Ligand Pharmaceuticals (LGND)	Supernus Pharmaceuticals (SUPN)	Eli Lilly and Company (LLY)
Revenue Growth (%)	167.27	-3.15	1.03	26.93	45.51
EBIT Growth (%)	34.77	-59.13	49.62	-106.87	70.32
Net Profit Growth (%)	28.47	-52.18	5.93	-129.41	49.79
EPS Growth (%)	30.63	-52.16	1.58	-124.42	50.65
Book Value Growth (%)	16.42	8.16	2.27	-3.75	70.28

Valuation Ratios

	BridgeBio Pharma (BBIO)	Dr. Reddy's Laboratories - ADR	Ligand Pharmaceuticals (LGND)	Supernus Pharmaceuticals (SUPN)	Eli Lilly and Company (LLY)
Price / Earnings	-20.69	0.19	32.11	-73.93	46.76
Price / Book Value	-7.27	0.03	3.93	2.68	36.37
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-25.47	0.00	19.27	60.71	31.56
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	BridgeBio Pharma (BBIO)	Dr. Reddy's Laboratories - ADR	Ligand Pharmaceuticals (LGND)	Supernus Pharmaceuticals (SUPN)	Eli Lilly and Company (LLY)
Debt to Equity	-1.16	0.03	0.00	0.00	1.17
Short term debt to equity ratio	-0.33	0.16	0.00	0.01	0.06
Current Ratio	2.09	1.93	13.35	2.49	1.39
Quick Ratio	2.03	1.40	13.35	2.19	1.00
Interest Coverage	-3.33	8.78	10.99	-13.11	30.52

Operating Efficiency Ratios

	BridgeBio Pharma (BBIO)	Dr. Reddy's Laboratories - ADR	Ligand Pharmaceuticals (LGND)	Supernus Pharmaceuticals (SUPN)	Eli Lilly and Company (LLY)
Debtors to sales (%)	39.67	30.73	32.79	24.82	29.18
Asset Turnover	0.43	0.46	0.12	0.45	0.49
Receivable days	52.44	115.08	70.50	83.79	93.67
Inventory Days	172.81	181.99	644.28	334.77	352.51
Payable days	296.14	56.23	234.84	17.79	142.23
Cash Conversion Cycle	-70.89	240.84	479.94	400.77	303.95

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly